375 reports of this reaction
2.0% of all DAPSONE reports
#10 most reported adverse reaction
DYSPNOEA is the #10 most commonly reported adverse reaction for DAPSONE, manufactured by Allergan, Inc.. There are 375 FDA adverse event reports linking DAPSONE to DYSPNOEA. This represents approximately 2.0% of all 19,006 adverse event reports for this drug.
Patients taking DAPSONE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for DAPSONE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for DAPSONE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 375 FDA reports for DAPSONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.0% of all adverse event reports for DAPSONE, making it a notable side effect.
If you experience dyspnoea while taking DAPSONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.